Camillo Ricord, MD
Camillo Ricordi, M.D. , Stacy Joy Goodman Professor of Surgery, Medicine, Biomedical Engineering, Microbiology and Immunology
Dr. Camillo Ricordi is Professor and Chief of the Division of Cellular Transplantation and Director of the Diabetes Research Institute at the University of Miami. Former president of CTS and IPITA, councilor of ASTS and TTS, he serves on several NIH Expert Panels, Strategic Planning committees, NCRR ICR Executive Committee, NIH CIT (chairperson); Ricordi serves also as ISMETT President of the Board (Mediterranean Institute for Transplantation and Advanced Therapies). Honors and awards include the 2001 World Prize of Surgery (University of Geneva) and the Outstanding Scientific Achievement Award (2002 Lilly Lecture, ADA Congress). Ricordi has authored over 500 publications and 7 patents.
SYNOPSIS OF AREA OF INTEREST: Development of cell therapy technologies and tolerance induction strategies for transplantation without continuous immunosuppression, and development of unlimited sources of insulin producing tissue (from xenografts to stem cells).
DETAILED AREA OF INTEREST: Dr. Ricordi's research objective is to develop a cure for Type 1 Diabetes, and he is known for pioneering islet isolation techniques that are now used worldwide and for performing the first successful series of human islet allografts. He contributed to the development of the first cGMP human islet cell processing facilities and to the standardization of human cell processing and transplant techniques protocols, from pre-clinical model systems to FDA Phase I/II and Phase III clinical trials. His major interests include the definition of strategies for immune tolerance induction, performing the first NIH funded, randomized prospective trials of donor bone marrow cell infusions to enhance allograft survival and most recently infusions of positively selected donor CD34+ cells with the objective to induce chimerism and avoid the need for chronic recipient immunosuppression. Research interests also include the development of effective strategies for manipulation of the micro-environment at the transplant site, to enhance initial post-transplant engraftment. Recent research also focuses on the development of effective ectopic transplant sites, through organ and tissue engineering, the use of hybrid devices for cell therapy with local immunomodulation and/or immunosuppression, and novel strategies for microencapsulation for immunoprotection. On the technology side, research interests include the development of automated methods for cell separation, remotely controlled cell processing equipment and telescience capability, new platform technologies for large scale cell culture, shipment of cell products across state barriers and the definition of novel pre-transplant potency tests that could predict post-transplant outcome.